Immune Cell Therapy Inc. Report issue

For profit Phase 1
Founded: Chicago IL United States (2003)
Status: Defunct (2018)

Organization Overview

First Clinical Trial
2012
NCT00793208
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Immune Cell, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Squamous Cell (Phase 1)

Leukemia (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lung Neoplasms (Phase 1)

Lymphoma (Phase 1)

Lymphoma, Large-Cell, Anaplastic (Phase 1)

Squamous Cell Carcinoma of Head and Neck (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 4
  • # of Trial APIs: 4